265 related articles for article (PubMed ID: 36214865)
1. Anticancer potential of oroxylin A: from mechanistic insight to synergistic perspectives.
Tuli HS; Garg VK; Kumar A; Aggarwal D; Anand U; Parashar NC; Saini AK; Mohapatra RK; Dhama K; Kumar M; Singh T; Kaur J; Sak K
Naunyn Schmiedebergs Arch Pharmacol; 2023 Feb; 396(2):191-212. PubMed ID: 36214865
[TBL] [Abstract][Full Text] [Related]
2. Oroxylin A inhibits carcinogen-induced skin tumorigenesis through inhibition of inflammation by regulating SHCBP1 in mice.
Huang H; Cai H; Zhang L; Hua Z; Shi J; Wei Y
Int Immunopharmacol; 2020 Mar; 80():106123. PubMed ID: 31927505
[TBL] [Abstract][Full Text] [Related]
3. Sesamol as a potent anticancer compound: from chemistry to cellular interactions.
Kumar A; Bajaj P; Singh B; Paul K; Sharma P; Mehra S; Robin ; Kaur P; Jasrotia S; Kumar P; Rajat ; Singh V; Tuli HS
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jan; ():. PubMed ID: 38180556
[TBL] [Abstract][Full Text] [Related]
4. Oroxylin A, a natural compound, mitigates the negative effects of TNFα-treated acute myelogenous leukemia cells.
Li H; Lu N; Yu X; Liu X; Hu P; Zhu Y; Shen L; Xu J; Li Z; Guo Q; Hui H
Carcinogenesis; 2018 Oct; 39(10):1292-1303. PubMed ID: 29346508
[TBL] [Abstract][Full Text] [Related]
5. Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells.
Zhao K; Zhou Y; Qiao C; Ni T; Li Z; Wang X; Guo Q; Lu N; Wei L
J Hematol Oncol; 2015 Apr; 8():41. PubMed ID: 25902914
[TBL] [Abstract][Full Text] [Related]
6. Oroxylin A inhibits invasion and migration through suppressing ERK/GSK-3β signaling in snail-expressing non-small-cell lung cancer cells.
Wei L; Yao Y; Zhao K; Huang Y; Zhou Y; Zhao L; Guo Q; Lu N
Mol Carcinog; 2016 Dec; 55(12):2121-2134. PubMed ID: 26741501
[TBL] [Abstract][Full Text] [Related]
7. The role of Nrf2 and apoptotic signaling pathways in oroxylin A-mediated responses in HCT-116 colorectal adenocarcinoma cells and xenograft tumors.
Hu R; Chen N; Yao J; Zhao Q; Zhang F; Li ZY; You QD; Guo QL
Anticancer Drugs; 2012 Jul; 23(6):651-8. PubMed ID: 22526619
[TBL] [Abstract][Full Text] [Related]
8. Oroxylin A Suppresses the Cell Proliferation, Migration, and EMT via NF-
Sun X; Chang X; Wang Y; Xu B; Cao X
Biomed Res Int; 2019; 2019():9241769. PubMed ID: 31341911
[TBL] [Abstract][Full Text] [Related]
9. Beclin 1-mediated autophagy in hepatocellular carcinoma cells: implication in anticancer efficiency of oroxylin A via inhibition of mTOR signaling.
Zou M; Lu N; Hu C; Liu W; Sun Y; Wang X; You Q; Gu C; Xi T; Guo Q
Cell Signal; 2012 Aug; 24(8):1722-32. PubMed ID: 22560876
[TBL] [Abstract][Full Text] [Related]
10. Cellular and molecular mechanisms of oroxylin A in cancer therapy: Recent advances.
Wang PX; Mu XN; Huang SH; Hu K; Sun ZG
Eur J Pharmacol; 2024 Apr; 969():176452. PubMed ID: 38417609
[TBL] [Abstract][Full Text] [Related]
11. Oroxylin A induces autophagy in human malignant glioma cells via the mTOR-STAT3-Notch signaling pathway.
Zou M; Hu C; You Q; Zhang A; Wang X; Guo Q
Mol Carcinog; 2015 Nov; 54(11):1363-75. PubMed ID: 25213258
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of Oroxylin A in rheumatoid arthritis.
Wang YL; Gao JM; Xing LZ
Int Immunopharmacol; 2016 Nov; 40():294-299. PubMed ID: 27643663
[TBL] [Abstract][Full Text] [Related]
13. Determination of oroxylin A and oroxylin A 7-O-d-glucuronide in HepG2 cell lysate and subcellular fractions with SPE-UPLC-MS/MS: Cellular pharmacokinetic study to indicate anti-cancer mechanisms.
Zhang Q; Cong D; An D; Fan A; Liu Q; Yi Y; Song Z; Chen X; Lu Y; Zhao D; He L
J Pharm Biomed Anal; 2018 May; 154():364-372. PubMed ID: 29571134
[TBL] [Abstract][Full Text] [Related]
14. Galangin: A metabolite that suppresses anti-neoplastic activities through modulation of oncogenic targets.
Tuli HS; Sak K; Adhikary S; Kaur G; Aggarwal D; Kaur J; Kumar M; Parashar NC; Parashar G; Sharma U; Jain A
Exp Biol Med (Maywood); 2022 Feb; 247(4):345-359. PubMed ID: 34904901
[TBL] [Abstract][Full Text] [Related]
15. Involvement of p53 in oroxylin A-induced apoptosis in cancer cells.
Mu R; Qi Q; Gu H; Wang J; Yang Y; Rong J; Liu W; Lu N; You Q; Guo Q
Mol Carcinog; 2009 Dec; 48(12):1159-69. PubMed ID: 19626645
[TBL] [Abstract][Full Text] [Related]
16. Oroxylin A sensitizes non-small cell lung cancer cells to anoikis via glucose-deprivation-like mechanisms: c-Src and hexokinase II.
Wei L; Dai Q; Zhou Y; Zou M; Li Z; Lu N; Guo Q
Biochim Biophys Acta; 2013 Jun; 1830(6):3835-45. PubMed ID: 23500080
[TBL] [Abstract][Full Text] [Related]
17. Oroxylin A Exerts Its Antitumor Effects in Human Gallbladder Cancer via Inhibition of the PTEN/PI3K/AKT Signaling Pathway.
Xuan L; Zhang J; Ji J; Hu J; Li F
Biol Pharm Bull; 2020; 43(10):1511-1518. PubMed ID: 32999161
[TBL] [Abstract][Full Text] [Related]
18. Modulation of diverse oncogenic signaling pathways by oroxylin A: An important strategy for both cancer prevention and treatment.
Sajeev A; Hegde M; Daimary UD; Kumar A; Girisa S; Sethi G; Kunnumakkara AB
Phytomedicine; 2022 Oct; 105():154369. PubMed ID: 35985182
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of 7-O-modified oroxylin A derivatives.
Fu W; Wang J; Yu L; Zhao L; Lu N; You Q; Guo Q; Li Z
Bioorg Med Chem Lett; 2012 Jan; 22(2):1118-21. PubMed ID: 22196122
[TBL] [Abstract][Full Text] [Related]
20. Oroxylin A suppresses invasion through down-regulating the expression of matrix metalloproteinase-2/9 in MDA-MB-435 human breast cancer cells.
Sun Y; Lu N; Ling Y; Gao Y; Chen Y; Wang L; Hu R; Qi Q; Liu W; Yang Y; You Q; Guo Q
Eur J Pharmacol; 2009 Jan; 603(1-3):22-8. PubMed ID: 19100732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
